热门资讯> 正文
iBio报告第三季度业绩
2024-05-14 05:12
- iBio press release (NYSE:IBIO): Q3 Cash, cash equivalents and restricted cash as of March 31, 2024 was approximately $6.4 million, inclusive of $1.1 million of restricted cash.
- No revenue was reported for the third quarter ended March 31, 2024.
More on iBio
- iBio climbs after AI-led drug discovery deal
- iBio announces $15 million private placement
- Financial information for iBio
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。